Pfizer Inc. said late Tuesday the Food and Drug Administration has approved its pneumonia vaccine Prevnar 13 for adults ages 18 through 49 and for infants and young children. The vaccine is already approved for adults over 50 and for children aged 6 to 17 years. The vaccine protects against 13 strains of bacteria causing pneumonia and other illnesses. Prevnar was first approved in the European Union for use in infants and young children in 2009, and is included in immunization programs in 102 countries, Pfizer said. Shares of Pfizer rose 0.1% in late trading after ending the regular session up 0.3%.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
From:: Stock Market News